课题基金 / 基金详情

KENNY CAFFY SYNDROME: BONE SCLEROSIS AND HYPOCALCEMIA

KENNY CAFFY SYNDROME: BONE SCLEROSIS AND HYPOCALCEMIA
肯尼·卡菲综合症:骨硬化和低钙血症
批准号:
6644201
负责人:
GEORGE A DIAZ
金额:
$12.96万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-07-15 至 2004-06-30

项目摘要

项目成果

GEORGE A DIAZ的其他基金

相关文献

中文摘要
翻译
此应用程序旨在为乔治A.迪亚兹,医学博士,博士与指导病人为导向的研究,这将有助于他作为一个独立的医生科学家的发展计划。迪亚兹博士已经完成了儿科住院医师的工作,在完成人类遗传学研究后,他将成为西奈山医学院人类遗传学和儿科助理教授。 在他的研究期间,他开始了常染色体隐性骨骼发育不良的定位克隆研究,肯尼-卡菲综合征(KCS),使用8个科威特血统。KCS的主要表现是身材矮小和低钙血症,但重要的其他表现包括眼睛异常,发育迟缓和免疫缺陷。虽然KCS是一种罕见的疾病,其独特的和多变的表现表明,疾病基因的鉴定将导致新的见解骨代谢和钙稳态以及其他受影响的器官系统,包括免疫和中枢神经系统的发展。在他的研究期间,迪亚兹博士进行了一个定位克隆项目,该项目要求他掌握连锁分析和物理作图。通过纯合性定位,KCS基因被成功定位于染色体Iq 42 -43,并通过单倍型分析确定KCS关键区域为约4cM的间隔。为了启动该区域的物理作图,使用简单串联重复序列和序列标记位点作为标记,通过PcR内容作图在关键区域构建YAC重叠群。为了鉴定KCS基因并阐明其功能,建议进行进一步的实验室和临床研究。这些研究将实现以下目标:1)通过开发新的多态性标记和鉴定新的KCS家族来缩小KCS关键区域; 2)进一步描绘KCS的自然史和表型特征,以获得对疾病发病机制和KCS基因功能的更多了解; 3)将继续使用PAC、BAC或粘粒克隆来进行关键区域的物理作图;以及4)评估KCS关键区域的候选基因,通过外显子捕获和cDNA选择分离新的转录物,并通过突变分析技术鉴定疾病基因。迪亚兹博士将在他的努力与保护研究时间,获得一般研究临床中心和机构的核心设施,专用实验室空间的支持。他的发展将由他的导师的认真承诺,以指导他在拟议的研究和研究的负责任的行为,并在西奈山杰出的研究和智力环境培育。
英文摘要
This application is designed to provide George A. Diaz, M.D., Ph.D. with a program of mentored patient-oriented research which will facilitate his development as an independent physician-scientist. Dr. Diaz has completed a residency in pediatrics and, upon completion of his fellowship in human genetics, will become an Assistant Professor of Human Genetics and Pediatrics at the Mount Sinai School of Medicine. During the course of his fellowship, he initiated positional cloning studies of an autosomal recessive skeletal dysplasia, the Kenny-Caffey Syndrome (KCS), using eight consanguineous Kuwaiti pedigrees. The principal manifestations KCS are short stature and hypocalcemia, but significant additional manifestations include eye abnormalities, developmental delay and immune deficits. Although KCS is a rare disease, its unique and protean manifestations suggest that identification of the disease gene will lead to novel insight into bone metabolism and calcium homeostasis as well as into the development of other affected organ systems, including the immune and central nervous systems. During the course of his fellowship, Dr. Diaz undertook a positional cloning project which required that he master linkage analysis and physical mapping. By homozygosity mapping, the KCS gene was successfully localized to chromosome Iq42-43, and the KCS critical region defined by haplotype analysis to an approximately 4 cM interval. To initiate physical mapping of the region, a YAC contig was constructed across the critical region by PcR content mapping using simple tandem repeats and sequence-tagged sites as markers. In order to identify the KCS gene and elucidate its function, further laboratory and clinical investigations are proposed. These studies will accomplish the following: l) the KCS critical region will be narrowed by development of new polymorphic markers and identification of new KCS families; 2) the natural history and phenotypic features of KCS will be further delineated to gain additional insight into the disease pathogenesis and the function of the KCS gene; 3) the physical mapping of the critical region will continue using PAC, BAC or cosmid clones; and 4) candidate genes in the KCS critical region will be evaluated, novel transcripts isolated by exon trapping and cDNA selection, and the disease gene will be identified by mutation analysis techniques. Dr. Diaz will be supported in his endeavors with protected research time, access to the General Research Clinical Center and institutional core facilities, and dedicated laboratory space. His development will be fostered by the serious commitment of his mentors to guide him in the proposed studies and in the responsible conduct of research, and by the outstanding research and intellectual environment at Mount Sinai.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LONGITUDINAL STUDY OF UREA CYCLE DISORDERS
GT4P COMPARED TO SODIUM PHENYLBUTYRATE IN UREA CYCLE DISORDERS
Chemokine Signaling Defects in Human Immunodeficiency
KENNY CAFFEY SYNDROME: BONE SCLEROSIS AND HYPOCALCEMIA